Current advances in prognostic and diagnostic biomarkers for solid cancers: Detection techniques and future...

Area of Science:

• Oncology and Cancer Research
• Biomarker Discovery
• Early Cancer Detection

Background:

• Solid cancers are a major cause of mortality, with tumor growth and metastasis posing significant challenges.
• While multimodal care improves survival, timely detection of resectable or metastatic tumors remains critical for prognosis.
• Identifying biomarkers for premalignant lesions is essential for improving patient outcomes in solid cancers.

Purpose of the Study:

• To review recent advancements in prognostic and diagnostic biomarkers for early detection of common solid cancers.
• To provide an overview of Food and Drug Administration (FDA)-approved biomarkers for solid tumors.
• To discuss conventional detection techniques and future opportunities in biomarker research.

Main Methods:

• Literature review of recent advancements in solid cancer biomarker research.
• Analysis of prognostic and diagnostic biomarker studies for breast, lung, colorectal, prostate, and stomach cancers.
• Examination of FDA-approved biomarkers and conventional detection methodologies.

Main Results:

• Significant progress has been made in identifying novel prognostic and diagnostic biomarkers for early cancer detection.
• Several FDA-approved biomarkers are available, but challenges remain in widespread clinical application.
• Conventional techniques are being refined, and new approaches are emerging to overcome detection hurdles.

Conclusions:

• Advancements in biomarker research offer promising strategies for enhancing early detection of solid cancers.
• Further research and development are needed to translate biomarker discoveries into effective clinical tools.
• Addressing current challenges in biomarker detection and validation is key to improving patient survival rates.